Therma Bright Inc. is a publicly traded company (TSVX:THRM) focused on servicing the $21 billion cosmeceutical industry. Therma Bright Inc. holds patents pending and the trademarks for Therozap™ and the trademark InterceptCS™ along with with regulatory approvals for its breakthrough thermal therapy technology. The Company’s technology uses heat and light energy to deliver effective, topical, pain free skin care.

Therma Bright Inc. has spent a significant investment in intellectual property and research and development for its InterceptCS™- cold sore device, the Therozap™ insect device, and will soon invest in a novel pain relief device.  Therma’s  current product lines address cold sore treatment and prevention, and the treatment of pain, itch and inflammation related to mosquito, bee, spider, mite, and jellyfish bites or stings. Therma Bright is in the research and development stage to develop a novel device for relief of pain associated with back, knee or other joint pain. Therma Bright is focused on building recurring revenue streams from its products and to incorporate intelligent technology such as AI or IoT.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

The Company is currently pursuing the redesign of Therma’s existing platforms to commercialize on new technologies.